Alphalyse, a fast-growing Danish specialist contract research organisation (CRO) that has developed GMP-validated liquid-chromatography mass-spectrometry (LC-MS) assays for host-cell-protein (HCP) impurity testing in biologic drugs, today announces that Fidelio Capital has acquired a majority stake in the company. Alphalyse’s founders will retain a significant shareholding, establishing an ambitious partnership aimed at expanding capacity, accelerating international growth, and establishing Alphalyse as the global reference in biologic HCP impurity analysis.
The partnership comes at an exciting moment for the biologics market as the drug pipeline – particularly complex modalities – continues to expand and the limitations of legacy ELISA technology become increasingly clear. LC-MS is emerging as the method of choice for drug developers and manufacturers seeking deeper process insight and stronger regulatory compliance, a trend underlined by the new U.S. Pharmacopeia (USP) General Chapter 1132.1 and recent discussions at the BEBPA Host Cell Protein Conference, where this shift was front and centre.
Alphalyse already supports customers at every development stage, from discovery to commercial release, with quantitative, reproducible HCP data that de-risks regulatory submissions and shortens development timelines. Its GMP-validated assays are fully in line with the new USP chapter, positioning the company to scale rapidly and set a new industry standard for HCP impurity analysis worldwide.
PMSI provided VCDD in support of the transaction, delivering an in-depth assessment of the market, including key themes such as the potential impact of new regulatory guidance on the adoption of LC-MS as the methodology of choice, as well as broader trends impacting the biotech sector.
Article
PMSI supports Foresight's investment into DP Me...
Foresight Group (“Foresight”), a FTSE 250 listed private equity and infrastructure investment manager, has completed a €5.3 million investment into DP Medica...